Wanxiwei (Pazopanib) 200mg*30 | Loncom China Generic | GLT

Generic Information: Wanxiwei (Pazopanib) 200mg — China-Mainland

Wanxiwei (万希维) is a Chinese generic of pazopanib manufactured by Shandong Loncom Pharmaceutical Co., Ltd., a Chinese pharmaceutical company. It is supplied as 200 mg tablets (0.2 g) in 30-tablet packs. Wanxiwei is one of the domestically approved pazopanib generics that provide an affordable, bioequivalent alternative to the originator Votrient for renal cell carcinoma and soft tissue sarcoma.

Chinese generic pazopanib has been included in China's national medical insurance scheme for the renal cell carcinoma indication, and domestic generics are priced well below the imported originator. For buyers seeking a cost-effective route to pazopanib, Wanxiwei offers the same active ingredient and dosing as the branded product.

What Is Wanxiwei Used For?

Wanxiwei treats advanced renal cell carcinoma (RCC) in the first-line setting and after prior cytokine therapy, and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. It delivers the same anti-angiogenic therapy as the originator pazopanib.

How Does Wanxiwei Work?

Pazopanib, the active ingredient in Wanxiwei, is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β) and c-Kit. By inhibiting these kinases, Wanxiwei disrupts tumour angiogenesis, reducing the blood supply that growing tumours depend on and slowing their progression.

Indications

• Advanced renal cell carcinoma (RCC), first-line and after prior cytokine therapy.
• Advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Dosage and Administration

The recommended dose is 800 mg once daily, taken as four 200 mg tablets on an empty stomach (at least 1 hour before or 2 hours after a meal), swallowed whole. A 30-tablet pack provides about one week of therapy. Dose adjustment is required for hepatic impairment, and liver function and blood pressure are monitored during treatment.

Side Effects

Common adverse reactions include diarrhoea, hypertension, hair colour changes, nausea, fatigue, decreased appetite and vomiting. Pazopanib carries a boxed warning for severe hepatotoxicity, requiring liver function monitoring before and during therapy. Hypothyroidism, haemorrhage and QT prolongation may occur, and patients should report yellowing, unusual bleeding or palpitations.

Storage

Store Wanxiwei below 30°C in the original pack, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT sources Wanxiwei through a documented China supply chain and confirms each batch against the manufacturer's details. Chinese generic pazopanib is typically priced at a small fraction of the branded originator's US list price, making long-term anti-angiogenic therapy far more sustainable. We provide clear purchase documentation and direct contact for ongoing support.

How to Order Wanxiwei from GLT

To order Wanxiwei 200 mg (30 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and order type, and we confirm batch details and lead time before dispatch.

FAQ

Is Wanxiwei the same as Votrient? Wanxiwei contains the same active ingredient (pazopanib) and is bioequivalent to Votrient; it is a Chinese generic by Shandong Loncom.

What is the standard dose? 800 mg once daily (four 200 mg tablets), taken on an empty stomach.

Where can I order Wanxiwei? GLT can supply Wanxiwei internationally; contact us on WhatsApp or email for availability.